1. Medtech Insight
  2. >>Policy & Regulation

CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

 
• By David Filmore and Sue Darcey

Industry is looking for a policy by the end of the year that would provide an automatic, temporary coverage pathway for breakthrough devices, and federal officials, including from the US Centers for Medicare and Medicaid Services (CMS) acknowledge they are actively looking at options for improving device reimbursement.

Medicare, Health Concept

Device industry leaders are optimistic that a formal breakthrough device reimbursement proposal could be on the table by the end of the year, and federal officials are certainly not giving any reason to doubt that.

Industry lobbyists have been working with CMS, members of Congress and other policymakers for years in an attempt to add more market-access predictably to highly innovative, high cost devices. Increasingly,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.